{
    "clinical_study": {
        "@rank": "116112", 
        "acronym": "InterAACT", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Active Comparator", 
                "description": "Cisplatin and 5-Fluorouracil"
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Experimental", 
                "description": "Carboplatin plus Paclitaxel"
            }
        ], 
        "brief_summary": {
            "textblock": "Anal cancer is a relatively uncommon disease and there is currently no standard chemotherapy\n      treatment for patients with inoperable locally recurrent or metastatic disease. The aim of\n      this phase II study is compare two well known and largely used chemotherapy regimens -\n      Cisplatin plus 5-fluorouracil vs Carboplatin plus Paclitaxel. The result of this study will\n      set a standard of care for this disease and provide useful information for future Phase III\n      trials."
        }, 
        "brief_title": "International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel", 
        "completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Squamous Cell Carcinoma of the Anus", 
        "condition_browse": {
            "mesh_term": [
                "Anus Neoplasms", 
                "Carcinoma", 
                "Carcinoma, Squamous Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study design: This is an international, multicentre, open label, randomised phase II trial.\n      Patients will be randomised to receive either cisplatin plus 5-FU or carboplatin plus weekly\n      paclitaxel. Region (Europe, North America, South America & Australia), (Eastern Cooperative\n      Oncology Group- ECOG) ECOG performance status (PS) (0-1 vs. 2), HIV status (positive vs.\n      negative) and extent of disease (locally recurrent vs. metastatic) will be used as\n      stratification factors. Overall response rate is the primary endpoint.\n\n      Indication: First line treatment of patients with inoperable locally recurrent or metastatic\n      squamous cell carcinoma of the anus.\n\n      Length of study: Recruitment should be completed within 3 years. The estimated recruitment\n      rate is between 4-6 patients per month once it is established at multiple centres.\n\n      Primary Objective: To evaluate best overall response rate by 24 weeks post treatment in the\n      cisplatin plus 5-fluorouracil arm versus the carboplatin plus weekly paclitaxel arm\n\n      Secondary Objectives: To evaluate: - Progression-free survival - Overall survival - Disease\n      control rate (stable disease or better) at 12 and 24 weeks - Best overall response of\n      metastatic lesions - Toxicity (graded according to the National Cancer Institute Common\n      Terminology Criteria for Adverse Events (NCI CTCAE Version 4) - Quality of Life (using EORTC\n      QLQ-C30 version 3 and EQ-5D-5L questionnaires).\n\n      To assess: The feasibility of conducting a multicentre international study on squamous cell\n      carcinoma of the anus and recruit within a reasonable time frame.\n\n      Exploratory Objective: Explorative biomarker analysis including the collection of archived\n      tumour tissue and blood sample at baseline and upon progression."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          1. Histologically or cytologically verified, uni-dimensionally measurable, inoperable,\n             locally recurrent or metastatic squamous cell carcinoma of the anus.\n\n          2. Age \u226518 years.\n\n          3. ECOG Performance status \u22642.\n\n          4. Measurable disease according to Response Evaluation Criteria in Solid Tumours\n             (RECIST) criteria version 1.1.\n\n          5. Previous definitive chemoradiotherapy is permitted for early stage squamous cell\n             carcinoma of the anus.\n\n          6. HIV+ patients will be considered eligible with a CD4 count of \u2265200.\n\n          7. Adequate cardiac and respiratory function; absolute neutrophil count (ANC)\n             \u22651.5x10^9/l; white blood cell (WBC) count \u22653x10^9/l; platelets >100x10^9/l;\n             haemoglobin (Hb) \u22659g/dl; creatinine clearance >50ml/minute; serum bilirubin \u22641.5x\n             upper limit of normal (ULN); alanine transaminase (ALT)/aspartate transaminase (AST)\n             \u22642.5x ULN; alkaline phosphatase (ALP) \u22643x ULN.\n\n          8. Fertile men and women must agree to take adequate contraceptive precautions during,\n             and for at least six months after therapy.\n\n          9. Life expectancy of at least 3 months.\n\n        Exclusion Criteria\n\n          1. Tumours of adenocarcinoma, melanoma, small cell and basal cell histology are\n             excluded.\n\n          2. Previous chemotherapy, radiotherapy or other investigational drug for surgically\n             unresectable locally recurrent or advanced squamous cell carcinoma of the anus\n\n          3. Current or recent (within 30 days of first study dosing) treatment with another\n             investigational drug or participation in another investigational study.\n\n          4. Documented or symptomatic brain metastases and/or central nervous system metastases\n             or leptomeningeal disease.\n\n          5. Surgery or palliative radiotherapy within 28 days of randomisation.\n\n          6. Clinically significant (i.e. active) cardiac disease (e.g. symptomatic coronary\n             artery disease, uncontrolled cardiac arrhythmia, or myocardial infarction within the\n             last 6 months). Any history of clinically significant cardiac failure.\n\n          7. History of interstitial lung disease (e.g. pneumonitis or pulmonary fibrosis) or\n             evidence of interstitial lung disease on baseline chest CT scan.\n\n          8. Lack of physical integrity of the gastro-intestinal tract, malabsorption syndrome\n             (naso-gastric or jejunostomy feeding tube is permitted).\n\n          9. Acute hepatitis C and/or chronic active hepatitis B infection.\n\n         10. Serious active infection requiring i.v. antibiotics at enrolment.\n\n         11. Other malignancy within the last 5 years, except for adequately treated carcinoma in\n             situ of the cervix or squamous carcinoma of the skin, or adequately controlled\n             limited basal cell skin cancer.\n\n         12. Other clinically significant disease or co-morbidity that may adversely affect the\n             safe delivery of treatment within this trial.\n\n         13. Known hypersensitivity to any of the study drugs or excipients.\n\n         14. Known peripheral neuropathy \u2265 grade 1 (absence of deep tendon reflexes as the sole\n             neurological abnormality does not render the patient ineligible).\n\n         15. Pre-existing hearing impairment.\n\n         16. Patients planning for a live vaccine.\n\n         17. Pregnant or lactating females."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02051868", 
            "org_study_id": "CCR 3847 InterAACT", 
            "secondary_id": "2013-001949-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A", 
                "description": "Cisplatin 60 mg/m2 as a 1 hour i.v. infusion once every 3 weeks.", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Systematic (IUPAC) name: (SP-4-2)-diamminedichloridoplatinum", 
                    "CAS number 15663-27-1 Y", 
                    "ATC code L01XA01"
                ]
            }, 
            {
                "arm_group_label": "Arm A", 
                "description": "5-FU 1000 mg/m2/24h as a 96-hour continuous infusion over days 1 to 4 every 3 weeks.", 
                "intervention_name": "5-Fluorouracil (5-FU)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Systematic (IUPAC) name: 5-fluoro-1H,3H-pyrimidine-2,4-dione", 
                    "CAS number 51-21-8 Y", 
                    "ATC code L01BC02"
                ]
            }, 
            {
                "arm_group_label": "Arm B", 
                "description": "Carboplatin 1-hour i.v. infusion to an area under the curve (AUC) of 5 once every 4 weeks.", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Systematic (IUPAC) name: cis-diammine(cyclobutane-1,1-dicarboxylate-O,O')platinum(II)", 
                    "CAS number 41575-94-4 Y", 
                    "ATC code L01XA02"
                ]
            }, 
            {
                "arm_group_label": "Arm B", 
                "description": "Paclitaxel 80 mg/m2 as a 1-hour i.v. infusion on day 1,8 and 15 of each (4-weekly) cycle.", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": [
                    "(2\u03b1,4\u03b1,5\u03b2,7\u03b2,10\u03b2,13\u03b1)-4,10-bis(acetyloxy)-13-{[(2R,3S)- 3-(benzoylamino)-2-hydroxy-3-phenylpropanoyl]oxy}- 1,7-dihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate", 
                    "CAS number 33069-62-4 Y", 
                    "ATC code L01CD01"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cisplatin", 
                "Fluorouracil", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Squamous cell carcinoma of the anus", 
            "Anal cancer", 
            "Cancer of the anus", 
            "SCCA", 
            "Cisplatin-5FU", 
            "Carboplatin-Paclitaxel", 
            "inoperable", 
            "locally recurrent", 
            "metastatic"
        ], 
        "lastchanged_date": "January 30, 2014", 
        "location": {
            "contact": {
                "email": "annette.bryant@rmh.nhs.uk", 
                "last_name": "Annette Bryant, BSc (Hons)", 
                "phone": "+44 (0) 0208 661 3637", 
                "phone_ext": "3637"
            }, 
            "facility": {
                "address": {
                    "city": "Sutton", 
                    "country": "United Kingdom", 
                    "zip": "SM2 5PT"
                }, 
                "name": "Royal Marsden NHS Foundation Trust, London & Sutton"
            }, 
            "investigator": {
                "last_name": "Sheela Rao, MD.FRCP", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease", 
        "overall_contact": {
            "email": "sheela.rao@rmh.nhs.uk", 
            "last_name": "Sheela Rao, MD, FRCP", 
            "phone": "+44 (0) 0208 642 6011", 
            "phone_ext": "1380"
        }, 
        "overall_contact_backup": {
            "email": "francesco.sclafani@rmh.nhs.uk", 
            "last_name": "Francesco Sclafani, MD", 
            "phone": "+44 (0)) 0208 642 6011", 
            "phone_ext": "1293"
        }, 
        "overall_official": {
            "affiliation": "Royal Marsden NHS Foundation Trust", 
            "last_name": "Sheela Rao, MD, FRCP", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United Kingdom: National Health Service", 
                "United Kingdom: National Institute for Health Research", 
                "United Kingdom: Research Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Best overall response rate is defined as the percentage of patients achieving confirmed partial or complete responses as per RECIST v1.1 by 24 weeks post treatment start in the intention to treat population. Sensitivity analyse will also be performed.", 
            "measure": "Best overall response rate by 24 weeks post treatment", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02051868"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The study will be conducted in approximately 50 international centres. This secondary endpoint will be measured by (i) the proportion of centres that successfully recruit at least one patient and (ii) overall recruitment rate. We anticipate and would be able to confirm feasibility if 80% of the centres fully engaged with the study. The aim would be to recruit 80 patients in 36 months (10 by month 6, 20 by month 12, 50 by month 24 and 80 by month 36).", 
                "measure": "Feasibility of conducting a multicentre, international study on squamous cell carcinoma of the anus and recruiting within a reasonable time frame.", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Toxicity will be graded according to the NCI CTCAE  Version 4.0", 
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "Toxicity will be analysed once all patients have been followed up for at least 4 weeks post treatment."
            }, 
            {
                "description": "This is calculated from the date of randomisation to the date of confirmed clinical/radiological progression or death from any cause. Patients who are lost to follow-up, withdraw from follow-up or alive and progression free will be censored at the date of last follow-up.", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "PFS will be analysed once all patients have been followed up for at least 12 months post treatment."
            }, 
            {
                "description": "This is calculated from the date of randomisation to the date of death from any cause. Patients, in whom no death is recorded, will be censored at the date they were last seen alive.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Overall survival will be analysed once all patients have been followed up for at least 12 months post treatment."
            }, 
            {
                "description": "Disease control rate is defined as complete response, partial response or stable disease, and will be assessed in accordance with the RECIST criteria v1.1.", 
                "measure": "Disease control rate", 
                "safety_issue": "No", 
                "time_frame": "12 and 24 weeks post treatment start"
            }, 
            {
                "description": "Best overall response of non-irradiated lesions is defined as the percentage of patients achieving confirmed partial response or complete response as per RECIST v1.1 of non-irradiated sites of disease.", 
                "measure": "Best overall response rate of non-irradiated lesions", 
                "safety_issue": "No", 
                "time_frame": "24 weeks post treatment start"
            }, 
            {
                "description": "Anti-tumour activity and magnitude of response will be captured by waterfall plot analyses and indicate the percentage change in tumour size from baseline to the time of best response.", 
                "measure": "Anti-tumour activity and magnitude of tumour response", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "Quality of Life will be evaluated using the EORTC QLQ C30 and EQ-5D-5L questionnaires. The functional and symptomatic scales and global health status from the QLQ C30 and EQ-5D-5L questionnaire will be calculated as per EORTC and EuroQol guidelines, respectively.", 
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Archived tumour tissue (if available) and blood sample will be taken at baseline with a repeat blood sample taken upon progression. Patient can enrol in an optional biomarker study where an additional tumour biopsy would be requested when they progress. The aim of this exploratory analysis is to evaluate the expression of tumour biomarkers in the study population and investigate the association of these with treatment outcome.", 
                "measure": "Identification of potential tumour biomarker", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Royal Marsden NHS Foundation Trust", 
        "sponsors": {
            "collaborator": {
                "agency": "Cancer Research UK", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Royal Marsden NHS Foundation Trust", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}